Cargando…

Genome-wide association studies in pharmacogenomics: untapped potential for translation

Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to...

Descripción completa

Detalles Bibliográficos
Autores principales: Guessous, Idris, Gwinn, Marta, Khoury, Muin J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684667/
https://www.ncbi.nlm.nih.gov/pubmed/19439031
http://dx.doi.org/10.1186/gm46
_version_ 1782167255002382336
author Guessous, Idris
Gwinn, Marta
Khoury, Muin J
author_facet Guessous, Idris
Gwinn, Marta
Khoury, Muin J
author_sort Guessous, Idris
collection PubMed
description Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to yield clinical applications. Certain methodological concerns, such as selection bias and confounding, may be mitigated when genome-wide association studies are conducted within clinical trials, in which randomization of exposure, prospective evaluation of outcome and careful definition of phenotype are incorporated by design.
format Text
id pubmed-2684667
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26846672010-04-23 Genome-wide association studies in pharmacogenomics: untapped potential for translation Guessous, Idris Gwinn, Marta Khoury, Muin J Genome Med Commentary Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to yield clinical applications. Certain methodological concerns, such as selection bias and confounding, may be mitigated when genome-wide association studies are conducted within clinical trials, in which randomization of exposure, prospective evaluation of outcome and careful definition of phenotype are incorporated by design. BioMed Central 2009-04-28 /pmc/articles/PMC2684667/ /pubmed/19439031 http://dx.doi.org/10.1186/gm46 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Commentary
Guessous, Idris
Gwinn, Marta
Khoury, Muin J
Genome-wide association studies in pharmacogenomics: untapped potential for translation
title Genome-wide association studies in pharmacogenomics: untapped potential for translation
title_full Genome-wide association studies in pharmacogenomics: untapped potential for translation
title_fullStr Genome-wide association studies in pharmacogenomics: untapped potential for translation
title_full_unstemmed Genome-wide association studies in pharmacogenomics: untapped potential for translation
title_short Genome-wide association studies in pharmacogenomics: untapped potential for translation
title_sort genome-wide association studies in pharmacogenomics: untapped potential for translation
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684667/
https://www.ncbi.nlm.nih.gov/pubmed/19439031
http://dx.doi.org/10.1186/gm46
work_keys_str_mv AT guessousidris genomewideassociationstudiesinpharmacogenomicsuntappedpotentialfortranslation
AT gwinnmarta genomewideassociationstudiesinpharmacogenomicsuntappedpotentialfortranslation
AT khourymuinj genomewideassociationstudiesinpharmacogenomicsuntappedpotentialfortranslation